Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1.41 INR
Change Today 0.00 / 0.00%
Volume 0.0
GRD On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

hindustan bio sciences ltd (GRD) Snapshot

Open
1.41
Previous Close
1.41
Day High
1.41
Day Low
1.41
52 Week High
09/17/14 - 2.15
52 Week Low
05/14/14 - 0.81
Market Cap
14.5M
Average Volume 10 Days
0.0
EPS TTM
-0.97
Shares Outstanding
10.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HINDUSTAN BIO SCIENCES LTD (GRD)

Related News

No related news articles were found.

hindustan bio sciences ltd (GRD) Related Businessweek News

No Related Businessweek News Found

hindustan bio sciences ltd (GRD) Details

Hindustan Bio Sciences Limited imports and markets recombinant human erythropoietin under the brand names of EPOVIN, EPOSINO, and TRANSFER & NEPHRODIL in India. The company was incorporated in 1991 and is based in Hyderabad, India.

Founded in 1991

hindustan bio sciences ltd (GRD) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hindustan bio sciences ltd (GRD) Key Developments

Hindustan Bio Sciences Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Hindustan Bio Sciences Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported total income from operations (net) of INR 2.250 million compared to INR 9.276 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 1.056 million compared to INR 0.468 million a year ago. Loss from ordinary activities before tax was INR 1.124 million compared to INR 0.536 million a year ago. Net loss for the period was INR 1.124 million or INR 0.11 per basic and diluted share compared to INR 0.536 million or INR 0.05 per basic and diluted share a year ago. For the nine months, the company reported total income from operations (net) of INR 5.957 million compared to INR 19.243 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 11.983 million compared to INR 5.684 million a year ago. Loss from ordinary activities before tax was INR 12.220 million compared to INR 5.875 million a year ago. Net loss for the period was INR 12.220 million or INR 1.19 per basic and diluted share compared to INR 5.875 million or INR 0.57 per basic and diluted share a year ago.

Hindustan Bio Sciences Ltd., Board Meeting, Jan 31, 2015

Hindustan Bio Sciences Ltd., Board Meeting, Jan 31, 2015. Agenda: To consider unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014.

Hindustan Bio Sciences Ltd. Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Hindustan Bio Sciences Ltd. reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2014. For the second quarter, the company reported income from operations of INR 3.498 million compared to INR 6.429 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 1.592 million compared to INR 2.191 million a year ago. Net loss from ordinary activates after tax was INR 1.692 million compared to INR 2.268 million a year ago. Net loss for the period was INR 1.692 million or INR 0.17 per share, compared to INR 2.268 million or INR 0.22 per share, a year ago. For the six months, the company reported income from operations of INR 3.707 million compared to INR 9.967 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 10.927 million compared to INR 5.216 million a year ago. Net loss from ordinary activates after tax was INR 11.096 million compared to INR 5.339 million a year ago. Net loss for the period was INR 11.096 million or INR 1.08 per share, compared to INR 5.339 million or INR 0.52 per share, a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRD:IN 1.41 INR 0.00

GRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GRD.
View Industry Companies
 

Industry Analysis

GRD

Industry Average

Valuation GRD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HINDUSTAN BIO SCIENCES LTD, please visit www.hindustanbiosciences.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.